Oncology News

Diabetes and high blood glucose levels among individuals without known diabetes correlated with increased risks for liver cancer and chronic liver disease, according results of a Chinese cohort study.

Every year, Healio Gastroenterology and Liver Disease meets with hepatology and gastroenterology experts to discuss their presentations on the latest research data, therapeutic updates, and recent advocacy programs.

Adherence to the Alternative Healthy Eating Index2010 dietary pattern may reduce the risk for hepatocellular carcinoma, according to a study published in Hepatology.

Extrahepatic cancer was more common in patients with hepatitis C and was the leading cause of death in patients who achieved sustained virologic response compared with the general population, according to results of a French cohort study.

The FDA granted orphan drug designation to M7824 for the treatment of biliary tract cancer.

Sorafenib combined with conventional transarterial chemoembolization for patients with advanced hepatocellular carcinoma improved time to progression, progression-free survival, and tumor response rate compared with sorafenib alone, according to a recently published study.

SAN FRANCISCO — Patients with advanced hepatocellular carcinoma with Child-Pugh B status experienced encouraging efficacy and safety outcomes after treatment with PD-1 inhibitor Opdivo, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Individuals with hepatitis C who underwent DAA therapy experienced significant reductions in both hepatocellular carcinoma and decompensation risk compared with untreated patients, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Starting this weekend, Healio Gastroenterology and Liver Disease will provide live coverage from The Liver Meeting 2018.

The FDA granted accelerated approval to pembrolizumab for the treatment of patients with hepatocellular carcinoma who received prior sorafenib.